Compare · MRNA vs TWST
MRNA vs TWST
Side-by-side comparison of Moderna Inc. (MRNA) and Twist Bioscience Corporation (TWST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and TWST operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $18.82B, about 4.4x TWST ($4.31B).
- Over the past year, MRNA is up 69.2% and TWST is up 109.9% - TWST leads by 40.7 points.
- TWST has been more active in the news (14 items in the past 4 weeks vs 13 for MRNA).
- MRNA has more recent analyst coverage (25 ratings vs 13 for TWST).
- Company
- Moderna Inc.
- Twist Bioscience Corporation
- Price
- $47.60+0.41%
- $70.04+1.35%
- Market cap
- $18.82B
- $4.31B
- 1M return
- -1.99%
- +19.68%
- 1Y return
- +69.23%
- +109.89%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2018
- News (4w)
- 13
- 14
- Recent ratings
- 25
- 13
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Latest MRNA
- Chief Financial Officer Mock James M converted options into 11,798 shares and covered exercise/tax liability with 5,705 shares, increasing direct ownership by 10% to 65,687 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Mock James M converted options into 2,475 shares and covered exercise/tax liability with 1,197 shares, increasing direct ownership by 2% to 59,594 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 2,165 shares and covered exercise/tax liability with 1,047 shares, increasing direct ownership by 2% to 67,468 units (SEC Form 4) (tax withholding)
- President Hoge Stephen converted options into 9,282 shares and covered exercise/tax liability with 4,488 shares, increasing direct ownership by 0.32% to 1,483,848 units (SEC Form 4) to satisfy tax liability
- Moderna to Present at Upcoming Conference in June 2026
- Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
- Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
- Chief Financial Officer Mock James M converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 0.98% to 58,316 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 0.86% to 66,350 units (SEC Form 4) (for tax liability)
- President Hoge Stephen converted options into 2,047 shares and covered exercise/tax liability with 990 shares, increasing direct ownership by 0.07% to 1,479,054 units (SEC Form 4) (tax liability)
Latest TWST
- Chief Financial Officer Laponis Adam sold $280,000 worth of shares (4,000 units at $70.00) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 112,675 units (SEC Form 4)
- Officer Cho Dennis sold $990,799 worth of shares (14,205 units at $69.75) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 120,094 units (SEC Form 4)
- Director Starovasnik Melissa A. sold $170,000 worth of shares (2,500 units at $68.00) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 22,222 units (SEC Form 4)
- Chief Executive Officer Leproust Emily M. exercised 16,470 shares at a strike of $8.82 and sold $1,118,555 worth of shares (16,470 units at $67.91) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Accounting Officer Werner Robert F. sold $49,987 worth of shares (800 units at $62.48), decreasing direct ownership by 2% to 48,186 units (SEC Form 4) (tax liability)
- Chief Executive Officer Leproust Emily M. exercised 49,299 shares at a strike of $8.82 and sold $3,213,653 worth of shares (49,299 units at $65.19) as part of a pre-agreed trading plan (SEC Form 4)
- Director Starovasnik Melissa A. sold $30,520 worth of shares (500 units at $61.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 24,722 units (SEC Form 4)
- Twist Bioscience to Present at William Blair 46th Annual Growth Stock Conference
- SVP of Human Resources Green Paula sold $74,507 worth of shares (1,399 units at $53.26), decreasing direct ownership by 1% to 121,589 units (SEC Form 4) (for tax liability)
- President and COO Finn Patrick John sold $221,549 worth of shares (4,160 units at $53.26), decreasing direct ownership by 1% to 274,804 units (SEC Form 4) (withholding obligation)